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Abstract: A simple and general “one pot” procedure for the 
synthesis of 2,9-diarylpurines with one or multiple hydroxyl 
groups in the 2- aryl unit is described, from the reaction of 5-
amino-4-amidinoimidazoles with phenolic aldehydes. 
Key words: nucleobases, phenols, condensations, aldehydes, 
ring closure. 
Purines have attracted attention of the scientific 
community mainly due to their biological activity.1 
During the last decade, purine derivatives were 
identified as a promising new class of antitubercular 
agents. The research was focused on the synthesis of 
nucleoside analogues as siderophore biosynthesis 
inhibitors,2 and on non nucleosides.3 In the non 
nucleoside series, purines having an aryl, a small alkyl 
or a proton on 9-N were essentially inactive, whereas 
9-benzyl-6-(2-furyl)purines,3b,h,j 9-sulfonyl-6-
mercaptopurines or 6-alkylthiopurines3e,k were highly 
potent. In addition, we recently described the first 
example of 2,9-diarylpurines (Figure 1) active against 
Mycobacterium tuberculosis.4 The results from 
biological evaluation showed that the potency of the 
compounds depends on the substituents in 9-N, 2-C 
and 6-C of the purine core. The presence of a 4-tolyl 
group in 9-N and a 3-hydroxyphenyl or a 4-
hydroxyphenyl substituent in 2-C combined with a 
secondary amine in 6-C proved to be important 
features for activity (Figure 1) but a clear structure-
activity correlation pattern could not be identified.4 
 
Figure 1 Hit compounds active on Mycobacterium tuberculosis 
A number of synthetic methods were developed to 
incorporate functional groups in the purine core, but 
costly reagents are usually required.5a,b In our research 
group purine derivatives have been obtained by a 
simple and inexpensive synthetic approach that uses 
the versatile reactivity of a substituted imidazole. 4,5c-l  
The 6-amino-2,9-diarylpurines (Figure 1) are a new 
promising scaffold active against Mycobacterium 
tuberculosis and the presence of hydroxyl groups in 
the aryl subunit in 2-C was considered an important 
feature for activity. The microorganism needs iron for 
the biochemical processes and multiple hydroxyl 
groups in the phenolic subunit could enhance the 
complexation with the metal. This perception 
prompted us to develop a new synthetic approach that 
would allow the efficient synthesis of purines 6 (table 
1) having a phenolic subunit in 2-C with two and three 
hydroxyl substituents. The previous method only 
allowed the introduction of phenolic units with one 
hydroxyl group as the reaction with polyphenolic 
aldehydes, performed in basic medium, was very slow 
(8-54 days) and extensive degradation occured.4 
Herein we describe a new and general synthetic 
approach for 6-amino-9-aryl-2-hydroxy or 2-
(polyhydroxyphenyl)purines 6 using imidazole 1, 
phenolic aldehydes 2 and a cascade of acid and basic 
catalysis. 
When compound 1a (Scheme 1) was combined with 
3,4,5-trihydroxybenzaldehyde 2a, in ethanol at 0 oC, 
using trifluoroacetic acid as catalyst, the starting 
materials were dissolved and a new white solid 
precipitated after 5 minutes. This compound was 
identified as the trifluoroacetate salt of starting 
material 3. When the reaction was repeated using 2.0 
equiv of the acid, a yellow solid precipitated after 4 
hours and was identified as 4a6 (Scheme 1).  
When imidazole 1b was reacted with monohydroxy or 
dihydroxyphenylaldehydes 2b or 2c, at 6 oC, no solid 
precipitated from the initial yellow solutions. When 
the TLC showed the absence of imines 4, off white 
solids were isolated and identified as dihydropurines 
5a,b7a (Scheme 1). Dihydropurine 5c was also isolated 
in the reaction of imidazole 1a with 3,4,5-
trihydroxyphenylaldehyde 2a when the reaction was 
carried out at room temperature (Scheme 1). The 
imine 4a also evolved to the dihydropurine 5c7b after 
10 days in ethanolic solution at 8 oC (Scheme 1).  
The pure imine 4a showed a single spot on TLC 
however, by 1H NMR, the spectrum obtained in 
DMSO solution showed signals consistent with the 
presence of two compounds in a 7:3 molar ratio. The 
major compound was identified as 4a (70%) and the 
minor compound as the dihydropurine 5c (30%). 
These results suggested that, in DMSO solution, the 
imine 4a was cyclizing to the dihydropurine 5c. In 
order to confirm this result a new 1H NMR spectrum 
was registered after 2 hours. The spectrum showed 
once again a mixture of 4a and 5c but in a 1:9 molar 
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Scheme 1 Reactions of imidazoles 1 with fenolic aldehydes 2 in acidic medium
ratio and this ratio did not change after one week, at 
room temperature. When the solution was heated in 
the NMR tube at 60 oC during 10 minutes a mixture of 
4a and 5c was still present, however new signals were 
observed in the spectrum, assigned to purine 6i, and to 
the imidazole 1a and aldehyde 2a, the starting 
reagents. The hydrolysis of the imine 4a was also 
observed by 1H NMR in an acidified solution of 4a in 
DMSO-d6. These results indicate that in DMSO 
solution, at room temperature, the imine 4a evolves 
rapidly to the dihydropurine 5c leading to an 
equilibrium mixture. Under heating, compound 5c 
evolves to generate the purine 6i. However, in acid  
 
Table 1 Synthesis of purines 6 
 
Imidazole (1) Aldehyde (2) Reaction conditions product        Yield 
 R1 R2  R3   (%) 
1b 4-MeC6H4 -N(CH2)4O 2b 2-HOC6H4 i) a) 1b (0.12 g), 2b (1.1 eq.), EtOH, TFA (1.3 eq), 11oC, 1 day 
b) DMSO (0.2 mL), Et3N(10 eq), 40oC, 2 days 
6a 73 
1b 4-MeC6H4 -N(CH2)4O 2d 3-HOC6H4 i) a) 1b (0.12 g), 2d(1.1 eq.), EtOH, TFA (1.3 eq), 11oC, 7 days 
b) DMSO (0.2 mL), Et3N(10 eq), 40oC, 2 days 
6b 79 
1b 4-MeC6H4 -N(CH2)4O 2e 4-HOC6H4 i) a) 1b (0.13 g), 2e (1.1 eq.), EtOH, TFA (1.3 eq), 11oC, 1 day 
b) DMSO (0.2 mL), Et3N(10 eq), 40oC, 2 days 
6c 78 
1b 4-MeC6H4 -N(CH2)4O 2f 2,3-(HO)2C6H3 i) a) 1b (0.17 g), 2f (1.1 eq.), EtOH), TFA (2.0 eq), r.t., 30 min 
b) DMSO, EtOH , Et3N(10 eq), 40oC, 6 days 
6d 88 
1b 4-MeC6H4 -N(CH2)4O 2c 3,4-(HO)2C6H3 i) a) 1b (0.12 g), 2c (1.1 eq.), EtOH, TFA (1.3 eq), 11oC, 1 day 
b) DMSO, Et3N(10 eq), 40oC, 4 days 
6e 58 
1b 4-MeC6H4 -N(CH2)4O 2g 2,3,4-(HO)3C6H2 i) a) 1b (0.30 g), 2g (1.1 eq.), EtOH, TFA (1.3 eq), r.t., 1 day 
b) DMSO, Et3N(10 eq), 40oC, 6 days 
6f 59 
1b 4-MeC6H4 -N(CH2)4O 2a 3,4,5-(HO)3C6H2 i) a) 1b (0.28 g), 2a (1.1 eq.), EtOH, TFA (1.3 eq), r.t., 6 days 
b) DMSO, Et3N(10 eq), 40oC, 1 day 
6g 50 
1a 4-MeC6H4 -N(CH2)5 2c 3,4-(HO)2C6H3 i) a) 1a (0.21 g), 2c (1.1 eq.), EtOH, TFA (1.5 eq), r.t., 6 days 
b) DMSO, Et3N(10 eq), 40oC, 4 days 
6h 57 
1a 4-MeC6H4 -N(CH2)5 2a 3,4,5-(HO)3C6H2 i) a) 1a (0.21 g), 2a (1.1 eq.), EtOH, TFA (1.5 eq), r.t., 10 days 
b) DMSO, Et3N(10 eq), 80oC, 1 day 
6i 57 
1c 4-MeC6H4 -N(CH2)4S 2a 3,4,5-(HO)3C6H2 i) a) 1c (0.16 g), 2a (1.1 eq.), EtOH, TFA (1.3 eq), r.t., 5 days 
b) DMSO, Et3N(10 eq), 80oC, 1 day 
6j 67 
1c 4-MeC6H4 -N(CH2)4S 2g 2,3,4-(HO)3C6H2 i) a) 1c (0.11 g), 2g (1.1 eq.), EtOH, TFA (1.3 eq), r.t., 4 days 
b) DMSO, Et3N(10 eq), 40oC, 5 days 
6k 60 
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solution, hydrolysis of the imine regenerates the 
starting materials 1a and 2a. 
The dihydropurine 5c was also solubilised in DMSO-
d6 and the 1H NMR spectrum, acquired after 5 
minutes, showed that 5c was the only product present 
in solution. However, after the addition of 
triethylamine and heating at 80 oC for 20 hours only 
purine 6i was present in solution. 
Considering that the reaction of imidazoles 1 with 
aldehydes 2, in ethanol in the presence of 1.3-2 equiv 
of TFA led to imines 4 and dihydropurines 5, and that 
compounds 4 and 5 in DMSO solution, under heating, 
and in the presence of triethylamine generated the 
desired purine 6, a new “one pot” synthetic procedure 
to generate purines 68 was designed, starting from 
imidazoles 1 and aldehydes 2. The reaction was 
initially carried out in ethanol and acid (1.3-2 equiv) 
until total consumption of the starting materials (by 
TLC). The solvent was then removed in the rotary 
evaporator and the reactions proceeded in DMSO and 
base, with heating. 
These experimental conditions were applied to the 
reaction of imidazoles 1a-c with aldehydes 2a-g, 
having one, two or three hydroxyl groups. The purines 
6a-k were obtained directly from the reaction mixture 
after 2-10 days (Table 1). When degradation was 
observed, the pure products were isolated in lower 
yields after dry flash chromatography (compounds 6e-
h). 
In summary this work describes a new versatile and 
simple “one-pot” method to synthesize 6-amino-9-
substituted-2-hydroxy or 2-
(polyhydroxyphenyl)purines 6 starting from 
imidazoles 1 and phenolic aldehydes 2. The formation 
of the imine intermediate, is favoured in ethanol using 
acid catalysis, however the cyclization and oxidation, 
to generate the purine core, is favoured in 
dimethylsulfoxide, under heating, using base catalysis. 
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(6) Procedure for the synthesis of imine 4a (Scheme 1): 
To a stirred suspension of imidazole 1a (0.14 g, 0.49 
mmol) in ethanol (0.4 mL), 1.1 equiv of aldehyde 2a 
(0.09 g, 1.1 equiv) and 2 equiv of TFA (75 L) were 
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added, at 0 oC. A yellow solution developed and a 
yellow solid started to precipitate after 25 minutes. 
When the TLC indicated the absence of starting material 
(4 h), ethanol was added (0.8 mL) and the yellow solid 
was filtered. The solid was washed with ethanol and 
diethyl ether and identified as compound 4a (0.22 g, 
0.40 mmol, 82 %). mp 124 – 126 oC. IR (Nujol mull): 
3498, 3352, 3210, 1665, 1626, 1604, 1586, 1521 cm-1. 
1H NMR (300 MHz, DMSO-d6):  = 1.62 (s, 6H, CH2), 
2.37 (s, 3H, CH3), 3.58 (br s, 4H, CH2), 6.82 (s, 2H, Ar-
H), 7.30–7.45 (m, 4H, Ar–H), 8.17 (s, 2H, 2-H, N=CH), 
8.80–9.60 (m, 5H, NH, HO, D2O exchangeable). Anal. 
calcd for C23H25N5O3·CF3COOH·H2O: C, 54.44; H, 
5.08; N, 12.70. Found: C, 54.68; H, 5.41; N, 12.45. 
(7) Procedure for the synthesis of dihydropurines 
5c(Scheme 1): Method i) Aldehyde 2a (0.07 g, 1.0 
equiv) and TFA (40 L,1.3equiv) were added to a stirred 
suspension of imidazole 1a (0.11 g, 0.40 mmol) in 
ethanol (2.0 mL), at room temperature. The yellow 
solution became light yellow and when TLC showed the 
absence of imine 4 (5 days), the solution was 
concentrated in the rotary evaporator. The off-white 
solid was filtered, washed with ethanol and diethyl ether 
and identified as compound 5c (0.09 g, 0.16 mmol, 41 
%). Method ii) A yellow ethanolic solution of 4a (0.09 
g, 0.16 mmol) was stirred at 8 oC until TLC showed the 
absence of starting material (10 days). The solution was 
concentrated in the rotary evaporator leading to an off-
white solid that was filtered and washed with diethyl 
ether and identified as compound 5c (0.08 g, 0.15 mmol, 
91%). mp 218–220 oC. IR (Nujol mull): 3535, 3202, 
1679, 1613, 1530 cm-1. 1H NMR (300 MHz, DMSO-
d6):  = 1.69 (s, 6H, CH2), 2.39 (s, 3H, CH3), 3.70 (m, 
4H, CH2), 5.71 (t, 1H, J = 4.8 Hz, 2-H), 6.28 (s, 2H, Ar-
H), 7.40-7.46 (m, 4H, Ar-H), 7.88 (s, 1H, 8-H), 8.07 (d, 
1H, J = 4.8 Hz, NH, D2O exchangeable), 8.23 (br s, 1H, 
HO, D2O exchangeable), 8.88 (d, 1H, J = 4.8 Hz, NH, 
D2O exchangeable), 8.99 (s, 2H, HO, D2O 
exchangeable). 13C NMR (75 MHz, DMSO-d6):  = 
20.62 (CH3), 23.32, 25.80, 48.82, 64.77 (2-C), 105.12, 
110.60, 124.14, 129.16, 130.32, 130.88, 133.39, 135.14 
(8-C), 138.65, 145.73, 145.84, 150.00. Anal. calcd for 
C23H25N5O3·CF3COOH·2.1H2O: C, 52.56; H, 5.29; N, 
12.26. Found: C, 52.55; H, 5.10; N, 12.07.  
(8) Procedure for the synthesis of purine 6f (Table 1): 
Aldehyde 2g (0.18 g, 1.1equiv) and TFA (166 L, 1.3 
equiv) were added to a stirred suspension of imidazole 
1b (0.30 g, 1.08 mmol) in ethanol (0.3 mL), at room 
temperature during 1 day. Then, the solvent was 
removed in the rotary evaporator, and DMSO (0.3 mL) 
was added to the crude solid followed by triethylamine 
(1.35 mL, 10 equiv) and the reaction was stirred at 40 
oC during 6 days. Addition of water and cooling for 10 
minutes led to a brown solid that was filtered and 
washed with water and diethyl ether (0.42 g). The brown 
solid was purified by dry flash chromatography on silica 
gel using 500 mL of diethyl ether as eluent to give an 
off-white solid identified as 6f (0.25 g, 0.60 mmol, 
59%). mp > 300 oC. IR (Nujol mull): 3550, 3465, 3337, 
3101, 1637, 1624, 1581, 1528 cm-1. 1H NMR (300 
MHz, DMSO-d6):  = 2.41 (s, 3H, CH3), 3.85 (s, 4H, 
CH2), 4.30 (br s, 4H, CH2), 6.36 (d, 1H, J = 9.0 Hz, Ar-
H), 7.43 (d, 2H, J = 8.4, Ar-H), 7.64 (d, 2H, J = 8.7 Hz, 
Ar-H), 7.68 (d, 1H, J = 9.0 Hz, Ar-H), 8.24 (br s, 1H, 
HO, D2O exchangeable), 8.45 (s, 1H, 8-H), 9.16 (br s, 
1H, HO, D2O exchangeable), 13.45 (s, 1H, HO, D2O 
exchangeable). 13C NMR (75 MHz, DMSO-d6):  = 
20.64 (CH3), 45.52, 66.13, 107.05, 111.53, 117.57, 
119.45, 123.82, 130.17, 131.99, 132.69, 137.77, 139.18 
(8-C), 148.54, 148.93, 149.36, 152.66, 158.86 (2-C). 
Anal. calcd for C22H21N5O4·0.5H2O: C, 61.68; H, 5.14; 
N, 16.36. Found: C, 61.75; H, 5.06; N, 16.20. 
 
 
 
 
 
 
 
 
